1. Home
  2. CTNM vs OIS Comparison

CTNM vs OIS Comparison

Compare CTNM & OIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • OIS
  • Stock Information
  • Founded
  • CTNM 2009
  • OIS 1995
  • Country
  • CTNM United States
  • OIS United States
  • Employees
  • CTNM N/A
  • OIS N/A
  • Industry
  • CTNM
  • OIS Metal Fabrications
  • Sector
  • CTNM
  • OIS Industrials
  • Exchange
  • CTNM Nasdaq
  • OIS Nasdaq
  • Market Cap
  • CTNM 328.1M
  • OIS 352.6M
  • IPO Year
  • CTNM 2024
  • OIS 2001
  • Fundamental
  • Price
  • CTNM $11.01
  • OIS $5.97
  • Analyst Decision
  • CTNM Strong Buy
  • OIS Hold
  • Analyst Count
  • CTNM 5
  • OIS 1
  • Target Price
  • CTNM $22.20
  • OIS $5.50
  • AVG Volume (30 Days)
  • CTNM 92.7K
  • OIS 584.0K
  • Earning Date
  • CTNM 10-30-2025
  • OIS 10-31-2025
  • Dividend Yield
  • CTNM N/A
  • OIS N/A
  • EPS Growth
  • CTNM N/A
  • OIS N/A
  • EPS
  • CTNM N/A
  • OIS 0.38
  • Revenue
  • CTNM N/A
  • OIS $655,119,000.00
  • Revenue This Year
  • CTNM N/A
  • OIS N/A
  • Revenue Next Year
  • CTNM N/A
  • OIS $5.16
  • P/E Ratio
  • CTNM N/A
  • OIS $15.66
  • Revenue Growth
  • CTNM N/A
  • OIS N/A
  • 52 Week Low
  • CTNM $3.35
  • OIS $3.08
  • 52 Week High
  • CTNM $20.24
  • OIS $6.88
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 48.88
  • OIS 45.23
  • Support Level
  • CTNM $10.77
  • OIS $6.54
  • Resistance Level
  • CTNM $11.34
  • OIS $6.88
  • Average True Range (ATR)
  • CTNM 0.68
  • OIS 0.27
  • MACD
  • CTNM -0.15
  • OIS 0.00
  • Stochastic Oscillator
  • CTNM 31.37
  • OIS 33.91

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About OIS Oil States International Inc.

Oil States International Inc is a provider of manufactured products and services to the energy, industrial and military sectors. Manufactured products include engineered capital equipment as well as products consumed in the drilling, well construction and production of oil and natural gas. The company sells its products and services to national oil and natural gas companies, oil and natural gas companies, onshore and offshore drilling companies and other oilfield services, defense and industrial companies. The company operates through three business segments, Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. It gains maximum revenue from Offshore Manufactured Products.

Share on Social Networks: